Detalles de la búsqueda
1.
Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.
Mod Pathol;
37(7): 100497, 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38641322
2.
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Mod Pathol;
36(4): 100100, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788081
3.
Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions.
Curr Oncol Rep;
25(5): 491-500, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36862337
4.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol;
23(5): 625-635, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405088
5.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res;
24(1): 58, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056374
6.
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer;
126(12): 1715-1724, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35194193
7.
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Mod Pathol;
35(12): 1804-1811, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842479
8.
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Breast Cancer Res;
23(1): 36, 2021 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33736679
9.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Int J Cancer;
148(10): 2614-2627, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533487
10.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res;
22(1): 47, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32408905
11.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer;
146(1): 262-271, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31162838
12.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer;
126(22): 4847-4858, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780421
13.
ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Genes Chromosomes Cancer;
58(3): 175-185, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30520184
14.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat;
175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
15.
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2ß.
Lab Invest;
98(1): 117-129, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29035379
16.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat;
165(3): 573-583, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664507
17.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Int J Cancer;
139(4): 882-9, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26946057
18.
The prognostic impact of age in different molecular subtypes of breast cancer.
Breast Cancer Res Treat;
152(3): 667-73, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26195120
19.
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Breast Cancer Res Treat;
150(2): 279-88, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25721604
20.
HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation.
Breast Care (Basel);
18(6): 455-463, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38125917